79 related articles for article (PubMed ID: 9179280)
41. Boosting T cell costimulation in cancer: the possibilities seem endless.
Evans DE; Weinberg AD
Int Rev Immunol; 2003; 22(2):173-94. PubMed ID: 12962274
[TBL] [Abstract][Full Text] [Related]
42. Real-time monitoring of immune responses.
Wieder ED
Cytotherapy; 2002; 4(4):347-52. PubMed ID: 12396835
[TBL] [Abstract][Full Text] [Related]
43. When should the immune clock be reset? From circadian pharmacodynamics to temporally optimized drug delivery.
Lévi F; Canon C; Dipalma M; Florentin I; Misset JL
Ann N Y Acad Sci; 1991; 618():312-29. PubMed ID: 2006792
[TBL] [Abstract][Full Text] [Related]
44. Defending and integrating an organism by the immune system.
Dembic Z
Scand J Immunol; 2022 May; 95(5):e13172. PubMed ID: 35416326
[TBL] [Abstract][Full Text] [Related]
45. Positive and negative selection, self-nonself discrimination and the roles of costimulation and anergy.
Mostardinha P; de Abreu FV
Sci Rep; 2012; 2():769. PubMed ID: 23101027
[TBL] [Abstract][Full Text] [Related]
46. Human acute lymphoblastic leukemia (ALL) blasts as accessory cells during T-cell activation: differences between patients in costimulatory capacity affect proliferative responsiveness and cytokine release by activated T cells.
Bruserud O; Ulvestad E
Cancer Immunol Immunother; 2003 Apr; 52(4):215-25. PubMed ID: 12669246
[TBL] [Abstract][Full Text] [Related]
47. Costimulatory molecules as immunotherapeutic targets in systemic lupus erythematosus.
Foell J; Mittler RS
Springer Semin Immunopathol; 2006 Oct; 28(2):153-62. PubMed ID: 16951932
[TBL] [Abstract][Full Text] [Related]
48. Autocrine costimulation: tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7-anti-CEA diabody fusion protein.
Blanco B; Holliger P; Alvarez-Vallina L
Cancer Gene Ther; 2002 Mar; 9(3):275-81. PubMed ID: 11896444
[TBL] [Abstract][Full Text] [Related]
49. Manipulation of T cell response to tumors by targeting on costimulatory pathway.
Chen L
Leukemia; 1997 Apr; 11 Suppl 3():567-9. PubMed ID: 9209456
[TBL] [Abstract][Full Text] [Related]
50. T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
Hombach A; Sent D; Schneider C; Heuser C; Koch D; Pohl C; Seliger B; Abken H
Cancer Res; 2001 Mar; 61(5):1976-82. PubMed ID: 11280755
[TBL] [Abstract][Full Text] [Related]
51. Requirements for stimulation or anergy induction in alloreactive human T cell clones.
Pawelec G; Kalbacher H; Pohla H; Boshell M; Max H; Friccius H; Adibzadeh M; Hambrecht A; Sansom D
Cell Immunol; 1994 Oct; 158(1):241-52. PubMed ID: 7522128
[TBL] [Abstract][Full Text] [Related]
52. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
53. Biologic response modifiers in acute lymphoblastic leukemia.
Gribben JG; Cardoso AA; Schultze JL; Nadler LM
Leukemia; 1997 May; 11 Suppl 4():S31-3. PubMed ID: 9179280
[TBL] [Abstract][Full Text] [Related]
54. Targeting costimulatory pathways for tumor immunotherapy.
Ward RC; Kaufman HL
Int Rev Immunol; 2007; 26(3-4):161-96. PubMed ID: 17558743
[TBL] [Abstract][Full Text] [Related]
55.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
56.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
57.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
58.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
59.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
